Applied Therapeutics Net Cash Flow 2020-2025 | APLT

Applied Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Applied Therapeutics Net Cash Flow 2020-2025 | APLT

Applied Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.1B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$134.7B
Vertex Pharmaceuticals (VRTX)$117.7B
Bristol Myers Squibb (BMY)$95B
CSL (CSLLY)$81.2B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$58.9B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.2B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18B
Illumina (ILMN)$15B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.9B
Incyte (INCY)$13B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12B
BioMarin Pharmaceutical (BMRN)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.8B